Aniracetam Bulk Powder

Aniracetam Bulk Powder is a positive allosteric modulator of the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor. Unlike other racetams, it is known to slow the rate of ion-channel closing, thereby enhancing glutamatergic transmission. It is also noted for its interactions with nicotinic acetylcholine receptors (nAChR) and its potential influence on dopaminergic and serotonergic systems.

1. Cognitive Enhancement Research
Aniracetam is widely used to explore its effects on memory impairment, particularly in animal models of vascular dementia and age-related cognitive decline. Researchers focus on its ability to improve learning and memory deficits by enhancing AMPA receptor-mediated synaptic transmission. Experimental indicators typically include behavioral paradigms such as the water maze test, passive avoidance task, and novel object recognition to assess the drug's effects on spatial memory, working memory, and long-term memory retention.

2. Neuropharmacology Research
In neuropharmacology, aniracetam is used as a tool to study the molecular mechanisms of synaptic plasticity, focusing on the induction and maintenance of long-term potentiation (LTP). Researchers observe its regulatory effect on synaptic transmission efficiency using ex vivo brain slice electrophysiological recordings (such as excitatory postsynaptic potential recordings in the CA1 region of the hippocampus). Furthermore, aniracetam is also used to evaluate its protective effects on neurons under hypoxic, oxidative stress, or chemical injury conditions; related experiments help elucidate the role of the glutamatergic system in neural adaptation and injury repair.

3. Behavioral Studies
At the behavioral level, aniracetam has demonstrated potential anxiolytic and antidepressant-like effects in animal models. Researchers used paradigms such as the elevated maze, light-dark box test, and open field test to assess its anxiolytic activity, and used forced swimming and tail suspension tests to detect its antidepressant-like behavioral performance. These effects are thought to be related to its indirect regulation of the dopaminergic and serotonergic systems, rather than solely relying on AMPA receptor mechanisms, suggesting the potential for multi-target applications of aniracetam in mood disorder-related research.

I. Common Adverse Reactions
Based on clinical experience, Aniracetam Bulk Powder is generally well tolerated at therapeutic doses, but the following adverse reactions may still occur:

Nervous System:

• Occasionally, drowsiness and dry mouth may occur, which disappear after discontinuation of the drug.
• Some users may experience symptoms such as excitement, headache, heaviness in the head, dizziness, delirium, insomnia, drowsiness, and anxiety.

Digestive System:

• Occasionally, belching, vomiting, diarrhea, loss of appetite, and abdominal pain may occur.

Skin and Allergic Reactions:

• Occasionally, rash and itching may occur.

Laboratory Abnormalities:

• Occasionally, elevated GOT, GPT, and ALP levels (liver function indicators) may occur.
• Occasionally, elevated BUN levels (kidney function indicators) may occur.

Others:

• Occasionally, facial flushing, tinnitus, and anemia may occur.

II. Irritant Phase Adverse Reactions

Due to its mild central nervous system stimulant effect, anisracetam may cause the following symptoms:

• Nervousness, irritability
• Insomnia
• Headache
• Nausea, vomiting

III. Serious Adverse Reactions and Risks

Reproductive Toxicity Risk (Requires Special Attention): Some data suggest that anisracetam may pose potential risks to the reproductive system, including:

• Improper fertility
• Possible harm to the fetus

It is important to note that an earlier animal toxicology study (1993) showed that in mice, rats, rabbits, and dogs, both single and repeated doses were well tolerated, with no adverse effects on the reproductive system observed. Mutagenicity tests were negative, and no carcinogenic potential was found with long-term administration. This study indicated that only very high doses showed mild toxic effects, and the therapeutic index was considered very broad. These two sets of information differ, and caution is advised when using anisracetam.

Aniracetam is contraindicated in the following populations:

1. Patients with hypersensitivity to anniracetam or any of its components
2. Patients with severe hepatic impairment or serious liver dysfunction
3. Patients with severe renal impairment (contraindicated in patients with severe hepatic or renal impairment)
4. Children and adolescents under 18 years of age (safety and efficacy data are insufficient)
5. Pregnant and lactating women should use with caution; safety is uncertain.

Our Aniracetam Bulk Powder uses premium packaging to ensure product purity and stability. The inner layer uses a food-grade, non-toxic vacuum-sealed bag to isolate moisture and prevent product spoilage. The outer packaging uses a high-strength cardboard box to avoid damage during transportation. 

Customized packaging (labeling, size) is available, conforming to international shipping standards, effectively protecting the product, and meeting the needs of personal use and bulk purchases.